IVA337 + IVA337 + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Alcoholic Steatohepatitis (NASH)

Conditions

Non-Alcoholic Steatohepatitis (NASH)

Trial Timeline

Feb 7, 2017 → Mar 16, 2020

About IVA337 + IVA337 + Placebo

IVA337 + IVA337 + Placebo is a phase 2 stage product being developed by Inventiva for Non-Alcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT03008070. Target conditions include Non-Alcoholic Steatohepatitis (NASH).

What happened to similar drugs?

0 of 4 similar drugs in Non-Alcoholic Steatohepatitis (NASH) were approved

Approved (0) Terminated (0) Active (4)
🔄GODEX + PlaceboCelltrionPhase 3
🔄Semaglutide + PlaceboNovo NordiskPhase 3
🔄Placebo + ResmetiromMadrigal PharmaceuticalsPhase 3
🔄ResmetiromMadrigal PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03008070Phase 2Completed

Competing Products

20 competing products in Non-Alcoholic Steatohepatitis (NASH)

See all competitors